47 results
425
SLRN
Acelyrin, Inc.
6 Feb 25
Business combination disclosure
7:47pm
Section 16(b)
Stockholder Litigation
Certain Tax Matters
Post-Closing Board of Directors
Termination of Company Plans
Employee Matters
ARTICLE VI …
Tax Representation Letters
-iii-
AGREEMENT AND PLAN OF MERGER
This AGREEMENT AND PLAN OF MERGER (this “Agreement”), dated as of February 6, 2025
425
EX-2.1
SLRN
Acelyrin, Inc.
6 Feb 25
Business combination disclosure
5:21pm
Litigation
Certain Tax Matters
Post-Closing Board of Directors
Termination of Company Plans
Employee Matters
ARTICLE VI CONDITIONS
Conditions to Each …
Interpretation; Construction
Certain Definitions
Exhibit A
Certificate of Incorporation of the Surviving Corporation
Exhibit B
Tax Representation Letters
425
EX-99.4
SLRN
Acelyrin, Inc.
6 Feb 25
Business combination disclosure
5:21pm
Company RSUs or Company PSUs settled in Subject Securities (to pay any Tax withholding obligations) or (B) transfers for receipt upon settlement
8-K
EX-99.3
SLRN
Acelyrin, Inc.
6 Feb 25
Entry into a Material Definitive Agreement
5:19pm
of such Securityholder’s Company RSUs or Company PSUs settled in Subject Securities (to pay any Tax withholding obligations) or (B) transfers for receipt
8-K
EX-2.1
SLRN
Acelyrin, Inc.
6 Feb 25
Entry into a Material Definitive Agreement
5:19pm
’ Insurance
Takeover Statutes
Section 16(b)
Stockholder Litigation
Certain Tax Matters
Post-Closing Board of Directors
Termination of Company Plans
Employee … of the Surviving Corporation
Exhibit B
Tax Representation Letters
-iii-
AGREEMENT AND PLAN OF MERGER
This AGREEMENT AND PLAN OF MERGER (this “Agreement”), dated
8-K
EX-10.1
4f761dr
10 Dec 24
ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis
4:34pm
S-3
EX-4.9
vplfrw1z6bxocj1r
13 Nov 24
Shelf registration
5:26pm
S-3
EX-4.10
dwj6pxflqs38
13 Nov 24
Shelf registration
5:26pm
S-3
d1jdjnrod
13 Nov 24
Shelf registration
5:26pm
S-3
EX-4.6
3d3canpbvewqvoscvs
13 Nov 24
Shelf registration
5:26pm
S-3
EX-4.8
9i54mh9 3lvy32yd
13 Nov 24
Shelf registration
5:26pm
S-3
EX-1.2
ntkyfj2trxm9 ykcscpv
13 Nov 24
Shelf registration
5:26pm
8-K
EX-99.1
w5tj k789d0
13 Nov 24
Independent Auditor’s Report
4:21pm
8-K
EX-10.1
dgs3d4tfi9sg50
13 Aug 24
Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial Results
4:14pm
8-K
EX-10.2
gtr9ajr 154o516f
9 May 24
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
8:13am
8-K
EX-10.1
lpcn owevygti
9 May 24
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
8:13am
DEF 14A
jy4 pfrin18k4oc
22 Apr 24
Definitive proxy
4:10pm